Researchers test needle-free injector for malaria
This article was originally published in Clinica
Executive Summary
Bioject Medical Technologies has begun a US Phase I clinical trial of its needle-free injector for delivering a vaccine for malaria. Researchers at the US Army Medical Research Institute of Infectious Diseases are testing the Biojector 2000 jet injector as a means of delivering a DNA-based vaccine made by US gene-based pharmaceutical company Vical. There are currently no available vaccines for malaria. Pharmaceutical company Merck recently pulled out of a deal with Bioject (see Clinica No 849, p 13).